Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

2,999 public trials 572 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Recruiting

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

NCT06083922

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Tufts Medical Center (Data Collection Only) Boston, Massachusetts, United States
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
View Trial Details
Recruiting

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Highlands Oncology Group Springdale, Arkansas, United States
  • Valkyrie Clinical Trials Los Angeles, California, United States
  • Emory University Atlanta, Georgia, United States
  • Nebraska Cancer Specialists Omaha, Nebraska, United States
View all 29 locations
View Trial Details
Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05160584

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • LKH Leoben Leoben, Austria
  • Krankenhaus der barmherzigen Schwestern Vienna, Austria
  • UZ Antwerpen Edegem, Belgium
  • Ziekenhuis Oost-Limburg Genk, Belgium
View all 90 locations
View Trial Details
Recruiting

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT05583617

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Prince of Wales Hospital Randwick, New South Wales, Australia
  • St Vincent's Hospital Melbourne Fitzroy, Victoria, Australia
  • CHU Lyon Sud - Service Hématologie Pierre-Bénite, France
  • IUCT Oncopole Toulouse, France
View all 16 locations
View Trial Details
Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

NCT05927571

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • Calvary Mater Newcastle Waratah, New South Wales, Australia
  • Royal Adelaide Hospital;Haematology Clinical Trials Unit Adelaide, South Australia, Australia
  • St. Vincent's Hospital Melbourne Melbourne, Victoria, Australia
View all 14 locations
View Trial Details
Recruiting

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

NCT06232044

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Mary Greeley Medical Center Ames, Iowa, United States
  • McFarland Clinic - Ames Ames, Iowa, United States
  • McFarland Clinic - Boone Boone, Iowa, United States
  • McFarland Clinic - Trinity Cancer Center Fort Dodge, Iowa, United States
View all 42 locations
View Trial Details
Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT05131022

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +37 more
Locations
  • City of Hope Duarte, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Yale Cancer Center New Haven, Connecticut, United States
View all 62 locations
View Trial Details

Related conditions